Acta Medica Iranica 2017. 55(4):218-227.

Distributions of High-Sensitivity C-Reactive Protein, Total Cholesterol-HDL Ratio and 10-Year Cardiovascular Risk: National Population-Based Study
Alipasha Meysamie, Saeed Ghodsi, Reza Ghalehtaki, Alireza Esteghamati, Fereshteh Asgari, Mohammad Mehdi Gouya


The present study aimed to evaluate the distributions of High-Sensitivity C-reactive protein, TC-HDL ratio and 10-year risk of cardiovascular diseases among Iranian adult population. We conducted a cross-sectional study on a total of 2125 adults aged 25 to 65. Data of the Third National Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) was used. Anthropometric indices, blood pressure and biochemical measurements had been obtained. Ten-year risk of cardiovascular events was also calculated using different models. Median (interquartile range) and geometric means (95% CI) of hs-CRP were 5.1(3.9) and 4.1(4.38-4.85), respectively. Mean TC-HDL ratio±(SD) was 5.94±2.84 in men and 5.37±1.97 in women (P<0.001). In spite of risk scores (FRS and SCORE), no significant gender and age-related differences were observed in hs-CRP levels. Exclusion of CRP levels≥10 did not change the results. The proportion of high-risk categories using SCORE and FRS models were 3.6 % and 8.8 %, respectively. In comparison with other published data, greater means and median values of High-Sensitivity C-reactive protein were observed. Higher TC-HDL ratio and cardiovascular risk in men than in women were also demonstrated. The issue of screening for cardiovascular diseases has yet to be addressed due to considerable prevalence of elevated CRP and increased risk of cardiovascular events among various subgroups.


C-reactive protein; Distribution; Cardiovascular risk scores; FRS; SCORE; TC-HDL

Full Text:



Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, et al. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation. 2004;109(21):2617-25. Epub 2004/06/03.

Libby P, Ridker PM. Inflammation and AtherothrombosisFrom Population Biology and Bench Research to Clinical Practice. Journal of the American College of Cardiology. 2006;48(9s1):A33-A46.

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. The New England journal of medicine. 2005;352(16):1685-95. Epub 2005/04/22.

Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. Journal of the American College of Cardiology. 2006;47(8 Suppl):C19-31. Epub 2006/04/25.

Roberts WL, Moulton L, Law TC, Farrow G, Cooper-Anderson M, Savory J, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clinical chemistry. 2001;47(3):418-25. Epub 2001/03/10.

Scirica BM, Morrow DA. Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation. 2006;113(17):2128-34; discussion 51. Epub 2006/05/03.

Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Annals of internal medicine. 2009;151(7):483-95. Epub 2009/10/07.

Wilson PW, Nam BH, Pencina M, D'Agostino RB, Sr., Benjamin EJ, O'Donnell CJ. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Archives of internal medicine. 2005;165(21):2473-8. Epub 2005/11/30.

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511. Epub 2003/01/29.

Ebrahimi M, Kazemi-Bajestani SM, Ghayour-Mobarhan M, Ferns GA. Coronary Artery Disease and Its Risk Factors Status in Iran: A Review. Iranian Red Crescent medical journal. 2011;13(9):610-23. Epub 2011/09/01.

Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European heart journal. 2003;24(11):987-1003. Epub 2003/06/06.

Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA : the journal of the American Medical Association. 2005;294(3):326-33. Epub 2005/07/21.

Esteghamati A, Meysamie A, Khalilzadeh O, Rashidi A, Haghazali M, Asgari F, et al. Third national Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC public health. 2009;9:167. Epub 2009/06/02.

WHO: STEPwise approach to surveillance (STEPS). Available from: http://

Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Annals of the New York Academy of Sciences. 1982;389:406-18. Epub 1982/01/01.

Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Annals of internal medicine. 1994;121(9):641-7. Epub 1994/11/01.

D'Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53. Epub 2008/01/24.

Ajani UA, Ford ES, Mokdad AH. Prevalence of high C-reactive protein in persons with serum lipid concentrations within recommended values. Clinical chemistry. 2004;50(9):1618-22. Epub 2004/06/19.

Ye X, Yu Z, Li H, Franco OH, Liu Y, Lin X. Distributions of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese people. Journal of the American College of Cardiology. 2007;49(17):1798-805. Epub 2007/05/01.

Wong ND, Pio J, Valencia R, Thakal G. Distribution of C-reactive protein and its relation to risk factors and coronary heart disease risk estimation in the National Health and Nutrition Examination Survey (NHANES) III. Preventive cardiology. 2001;4(3):109-14. Epub 2002/02/06.

Tohidi M, Hadaegh F, Harati H, Azizi F. C-reactive protein in risk prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. International journal of cardiology. 2009;132(3):369-74. Epub 2008/02/05.

Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, et al. Race and gender differences in C-reactive protein levels. Journal of the American College of Cardiology. 2005;46(3):464-9. Epub 2005/08/02.

Hutchinson WL, Koenig W, Frohlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clinical chemistry. 2000;46(7):934-8. Epub 2000/07/15.

Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004;109(11):1349-53. Epub 2004/03/17.

Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation. 2003;108(2):161-5. Epub 2003/07/02.

Labonte ME, Dewailly E, Chateau-Degat ML, Couture P, Lamarche B. Population-based study of high plasma C-reactive protein concentrations among the Inuit of Nunavik. International journal of circumpolar health. 2012;71. Epub 2012/10/23.

Linn S, Fulwood R, Carroll M, Brook JG, Johnson C, Kalsbeek WD, et al. Serum total cholesterol: HDL cholesterol ratios in US white and black adults by selected demographic and socioeconomic variables (HANES II). American journal of public health. 1991;81(8):1038-43. Epub 1991/08/01.

Arsenault BJ, Rana JS, Stroes ES, Despres JP, Shah PK, Kastelein JJ, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. Journal of the American College of Cardiology. 2009;55(1):35-41. Epub 2010/02/02.

Araujo F, Pereira AC, Latorre Mdo R, Krieger JE, Mansur AJ. High-sensitivity C-reactive protein concentration in a healthy Brazilian population. International journal of cardiology. 2004;97(3):433-8. Epub 2004/11/25.

Marques-Vidal P, Rodondi N, Bochud M, Chiolero A, Pecoud A, Hayoz D, et al. Predictive accuracy of original and recalibrated Framingham risk score in the Swiss population. International journal of cardiology. 2009;133(3):346-53. Epub 2008/05/20.

Bhopal R, Fischbacher C, Vartiainen E, Unwin N, White M, Alberti G. Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data. J Public Health (Oxf). 2005;27(1):93-100. Epub 2005/03/08.

Ford ES, Giles WH, Mokdad AH. The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. Journal of the American College of Cardiology. 2004;43(10):1791-6. Epub 2004/05/18.

Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA : the journal of the American Medical Association. 2008;300(2):197-208. Epub 2008/07/10.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.